Comparative Pharmacology
Head-to-head clinical analysis: LYMPHOSEEK KIT versus PROSTASCINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYMPHOSEEK KIT versus PROSTASCINT.
LYMPHOSEEK KIT vs PROSTASCINT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.
Pre-dose: 20 mcg (0.5 mL) intradermally followed by 0.5 mL subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 mL (20 mcg) subcutaneously.
5 mCi (185 MBq) intravenously over 5 minutes, single dose.
None Documented
None Documented
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
Terminal elimination half-life: 2.6 ± 0.7 days (requires 2 weeks for complete clearance; used for radioimmunodetection within 5–7 days post-injection)
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Renal: ~90% (predominantly as intact tracer), Fecal: <5%
Category C
Category C
Radiopharmaceutical Diagnostic Agent
Radiopharmaceutical Diagnostic Agent